TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18978490

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg daily for 3 weeks, then 10 mg daily for 3 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 26
Study: 17724715

Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (LBC) plus HPV
Number of subjects: 28000

Group type: EXPERIMENTAL
Intervention: HPV testing
Number of subjects: 28000

Group type: EXPERIMENTAL
Intervention: HPV testing with cytology-triage
Number of subjects: 28000

Group type: COMPARATOR
Intervention: Conventional Pap test
Number of subjects: 28000
Study: 15464185

Group type: EXPERIMENTAL
Intervention: 2EHRZ/6HE
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: 2(EHRZ)3/6HE
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: 2EHRZ/4HR
Number of subjects: 1355

Group type: COMPARATOR
Intervention: 6-month standard regimen
Number of subjects: 1355
Study: 11588522

Group type: EXPERIMENTAL
Intervention: nitrendipine (20 mg/d)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: trandolapril (2 mg/d)
Number of subjects: 39
Study: 9682676

Group type: EXPERIMENTAL
Intervention: Skin cooling (chilling of the integument of their heads and thoraces for 30 min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No cooling (control phase)
Number of subjects: 10
Study: 8003306

Group type: EXPERIMENTAL
Intervention: Low intensity laser irradiation (9.6 J/cm2, 830 nm)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo or control groups
Number of subjects: 51
Study: 2574764

Group type: EXPERIMENTAL
Intervention: Tiludronate 100 mg daily for 6 months
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 76
Study: 31746051

Group type: EXPERIMENTAL
Intervention: Regular penis-root masturbation (PRM)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Kegel exercise (KE)
Number of subjects: 37
Study: 29588137

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 mg per day)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 U per week)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 28389801

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia with ropivacaine and fentanyl (Epi PCA group)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia with fentanyl (IV PCA group)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Epidural PCA group
Number of subjects: 86

Group type: COMPARATOR
Intervention: IV PCA group
Number of subjects: 86
Study: 26268910

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: 5 mg CCX140-B
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: 10 mg CCX140-B
Number of subjects: 332
Study: 24157585

Group type: EXPERIMENTAL
Intervention: Slow intravenous injection of photosensitizer during the first 15 minutes of irradiation (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fomentation before photosensitizer injection and irradiation (Group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional injection method (Control Group C)
Number of subjects: 30
Study: 21905248

Group type: EXPERIMENTAL
Intervention: Continuous clinical remission (CR; DAS <1.6)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Continuous high disease activity (HDA; DAS >2.4)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Low disease activity (LDA; 1.6 ≥ DAS ≤ 2.4)
Number of subjects: 145
Study: 18990735

Group type: EXPERIMENTAL
Intervention: Disparity articles (emphasizing impact, two dimensions of disparity)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Progress articles (emphasizing improvement over time)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Disparity articles
Number of subjects: 300
Study: 17078211

Group type: EXPERIMENTAL
Intervention: B+Q (Quinapril)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: B+V (Valsartan)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: B+Q+V (Quinapril + Valsartan)
Number of subjects: 63
Study: 15327612

Group type: EXPERIMENTAL
Intervention: Video monitoring of smear-taking at colposcopy
Number of subjects: 272
Study: 11561779

Group type: EXPERIMENTAL
Intervention: High-dose etoposide (3 x 400 mg/m2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Etoposide phosphate (equimolar amount to etoposide)
Number of subjects: 10
Study: 9243169

Group type: EXPERIMENTAL
Intervention: Sodium citrate (CIT) at a dose of 0.5 g.kg‐1 body mass
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sodium citrate (CIT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Sodium citrate (CIT) and Placebo (PLC)
Number of subjects: 8
Study: 8488172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306

Group type: COMPARATOR
Intervention: Cimetidine 400 mg at bedtime
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: DL-cysteine 200 mg 4 times daily
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: DL-methionine-methyl sulphonium chloride (MMSC) 500 mg 4 times daily
Number of subjects: 306
Study: 3552683

Group type: EXPERIMENTAL
Intervention: High-dose IV Metoclopramide (1 mg/kg/dose X 5 doses)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Combination of Metoclopramide (same schedule) plus Nortriptyline (50 mg PO X 2 doses) plus Thiethylperazine (10 mg IV X 3 doses)
Number of subjects: 26
Study: 30077178

Group type: EXPERIMENTAL
Intervention: 400 mg/d algal-derived DHA
Number of subjects: 957

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 957
Study: 27477773

Group type: EXPERIMENTAL
Intervention: Statin-based therapy
Number of subjects: 183419
Study: 25137523

Group type: EXPERIMENTAL
Intervention: Hot saline irrigation (HSI) at 49°C, 20 mL every 10 minutes during FESS
Number of subjects: 62

Group type: COMPARATOR
Intervention: Room temperature saline irrigation (RTSI) at 18°C, 20 mL every 10 minutes during FESS
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Heart rate
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Mean arterial blood pressure (MABP)
Number of subjects: 62
Study: 23869107

Group type: EXPERIMENTAL
Intervention: Butylscopolamine 20 mg i.v.
Number of subjects: 57

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 57
Study: 20216025

Group type: EXPERIMENTAL
Intervention: Ultrasound imaging for regional anesthesia
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Ultrasound imaging for peripheral nerve blocks
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Ultrasound imaging for neuraxial anesthesia
Number of subjects: 211

Group type: COMPARATOR
Intervention: Ultrasound imaging
Number of subjects: 211
Study: 19115656

Group type: EXPERIMENTAL
Intervention: 36 ml of levobupivacaine 0.1%
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 72 ml of levobupivacaine 0.1%
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 36 ml of levobupivacaine 0.25%
Number of subjects: 110
Study: 16329083

Group type: EXPERIMENTAL
Intervention: Day-care laparoscopic cholecystectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Overnight-stay laparoscopic cholecystectomy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Quality of life assessment using HADS and PGWB
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cost analysis
Number of subjects: 100
Study: 12598550

Group type: EXPERIMENTAL
Intervention: CPP‐ACP-containing mouthrinse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPP‐ACP-containing chewing gum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other forms of calcium (in comparison)
Number of subjects: 0
Study: 10992172

Group type: EXPERIMENTAL
Intervention: Dual-energy x-ray absorptiometry scan
Number of subjects: 1610
Study: 8970819

Group type: EXPERIMENTAL
Intervention: Aspirin (3 x 320 mg capsules every 6 h for 3 days, total 3.84 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (identical schedule as aspirin)
Number of subjects: 0
Study: 1385090

Group type: EXPERIMENTAL
Intervention: Conditioning stimulus (peripheral nerve stimulus)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: C-T paradigm
Number of subjects: 16
Study: 2868900

Group type: EXPERIMENTAL
Intervention: endralazine 5 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study: 29748932

Group type: EXPERIMENTAL
Intervention: Metformin 500 or 1000 mg twice daily for 37 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Metformin in obese adolescents
Number of subjects: 22
Study: 27647769

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (ABO) intradermal injection at 1:7 cc dilution (500 unit in 7 cc of NSS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal saline solution (NSS)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (ABO) intradermal injection
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Age younger than 32 receiving AbobotulinumtoxinA (ABO)
Number of subjects: 22
Study: 23636866

Group type: EXPERIMENTAL
Intervention: Urethral dilatation (UD) plus cystoscopy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cystoscopy alone
Number of subjects: 50
Study: 22886431

Group type: EXPERIMENTAL
Intervention: Diode laser treatment at fluences of 7 J/cm²
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Diode laser treatment at fluences of 12 J/cm²
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Diode laser treatment at fluences of 20 J/cm²
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (untreated area)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Diode laser treatment
Number of subjects: 13
Study: 20942239

Group type: EXPERIMENTAL
Intervention: Bronchial lavage (BL) with 1% lidocaine (2 ml) and 0.125% metronidazole (5 ml) during bronchoscopic procedure
Number of subjects: 123

Group type: COMPARATOR
Intervention: Rigid bronchoscopic retrieval of foreign bodies under general anaesthesia (Control group)
Number of subjects: 123
Study: 18307585

Group type: EXPERIMENTAL
Intervention: Olanzapine, Risperidone, Haloperidol
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (matched healthy controls)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (Olanzapine, Risperidone, Haloperidol)
Number of subjects: 99
Study: 16297488

Group type: EXPERIMENTAL
Intervention: 2-year lifestyle intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study: 12418584

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 194

Group type: COMPARATOR
Intervention: Ex-smokers
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Patients with initial FEV1 in the range 30-65% predicted
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: FEV1 slopes calculated using first four assessments
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Post-bronchodilator values
Number of subjects: 194
Study: 10435809

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy in p53 negative patients
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy in p53 positive patients
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Interaction between p53 status and benefit of radiotherapy
Number of subjects: 163
Study: 7812552

Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS)
Number of subjects: 57
Study: 2297337

Group type: EXPERIMENTAL
Intervention: Test drug in one eye
Number of subjects: 396

Group type: COMPARATOR
Intervention: Placebo in the fellow eye
Number of subjects: 396
Study: 101843

Group type: EXPERIMENTAL
Intervention: Four-drug combination (hexamethylmelamine, cyclophosphamide, methotrexate, 5-fluorouracil)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Melphalan
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients with minimal residual disease
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients with advanced disease achieving complete remission
Number of subjects: 80
Study: 30761945

Group type: EXPERIMENTAL
Intervention: Move-A-Thon (MAT) event with monetized donations to charity, incentivizing participants to achieve a minimum of 3,000 daily steps for 2 weeks.
Number of subjects: 8
Study: 28795638

Group type: EXPERIMENTAL
Intervention: Legflow paclitaxel‐eluting balloon (PEB) + Supera stenting
Number of subjects: 160

Group type: COMPARATOR
Intervention: Supera stenting alone
Number of subjects: 160
Study: 25882198

Group type: EXPERIMENTAL
Intervention: Self-generated strategies
Number of subjects: 120

Group type: COMPARATOR
Intervention: Taught strategies
Number of subjects: 120
Study: 24012453

Group type: EXPERIMENTAL
Intervention: PMT plus thrombolysis
Number of subjects: 69

Group type: COMPARATOR
Intervention: Thrombolysis alone
Number of subjects: 69
Study: 21871998

Group type: EXPERIMENTAL
Intervention: Grade 3 ischemia (G3I)
Number of subjects: 1308
Study: 19463196

Group type: EXPERIMENTAL
Intervention: Five-step clinical pathway implementation process
Number of subjects: 180

Group type: COMPARATOR
Intervention: Hard copy of Australian national guidelines for chest pain and AMI management
Number of subjects: 180
Study: 19153426

Group type: EXPERIMENTAL
Intervention: Drug-eluting stent (DES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 0
Study: 11100449

Group type: EXPERIMENTAL
Intervention: Rhodifuse Iode system (iodine release system) used in three villages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no iodine release system) in one village
Number of subjects: 0
Study: 8866933

Group type: EXPERIMENTAL
Intervention: ORG 2766 (40 mg for 6 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ORG 2766 (responders)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (responders)
Number of subjects: 50
Study: 1299257

Group type: EXPERIMENTAL
Intervention: Rubber dam isolation
Number of subjects: 694

Group type: COMPARATOR
Intervention: Cotton roll isolation
Number of subjects: 694
Study: 6509234

Group type: EXPERIMENTAL
Intervention: Full package of environmental changes and toilet training at peak evacuation times (Ward A)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Combination of two-hourly toileting for five weeks and environmental changes (Ward B)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Only environmental changes (Ward C)
Number of subjects: 3
Study: 31664594

Group type: EXPERIMENTAL
Intervention: Noise30 (30 train noise events, 52 dB(A))
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Noise60 (60 train noise events, 54 dB(A))
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (background noise, 33 dB(A))
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Noise30
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Noise60
Number of subjects: 70
Study: 28940316

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 0
Study: 26667449

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg QD
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg Q-MWF
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Letrozole 1.0 mg Q-MWF
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Letrozole 0.25 mg Q-MWF
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control (standard dose arm)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: All dose arms
Number of subjects: 112
Study: 25419767

Group type: EXPERIMENTAL
Intervention: Active surveillance cultures from nares, oropharynx, groin, perianal area, wounds, and device insertion sites
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Screening extranasal sites
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Indwelling device insertion sites, groin, and perianal area
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Healthcare-associated MRSA strains (USA100 and USA100 variants)
Number of subjects: 120
Study: 22487197

Group type: EXPERIMENTAL
Intervention: Adolescents and adults (young, middle-aged, and older) with 25(OH)D levels ≤50 nmol/L in winter/spring
Number of subjects: 2075

Group type: EXPERIMENTAL
Intervention: Adolescents and adults (young, middle-aged, and older) with 25(OH)D levels ≤25 nmol/L in winter/spring
Number of subjects: 2075

Group type: EXPERIMENTAL
Intervention: Primary schoolchildren with 25(OH)D levels <50 nmol/L
Number of subjects: 2075

Group type: EXPERIMENTAL
Intervention: Primary schoolchildren with 25(OH)D levels ≤25 nmol/L
Number of subjects: 2075

Group type: EXPERIMENTAL
Intervention: Adolescents and adults with 25(OH)D levels ≤50 nmol/L in summer/autumn
Number of subjects: 2075

Group type: EXPERIMENTAL
Intervention: Adolescents and adults with 25(OH)D levels ≤25 nmol/L in summer/autumn
Number of subjects: 2075

Group type: EXPERIMENTAL
Intervention: Adolescents and adults with highest category of sun exposure in winter/spring
Number of subjects: 2075
Study: 20737278

Group type: EXPERIMENTAL
Intervention: Local warming at injection site using an air‐warming device at 40°C for 1 minute prior to injecting 1 ml (10 mg) of rocuronium.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no warming).
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Local warming at injection site.
Number of subjects: 90
Study: 18614726

Group type: COMPARATOR
Intervention: F+0 (control) - 6 microg Se/L
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: F+7 - 13 microg Se/L
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: F+15 - 21 microg Se/L
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: BF - breastfed reference group (11 +/- 2 microg Se/L)
Number of subjects: 161
Study: 15905981

Group type: EXPERIMENTAL
Intervention: Transient ischemic attack (TIA)
Number of subjects: 548

Group type: COMPARATOR
Intervention: Stroke
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: TIA
Number of subjects: 548
Study: 12368787

Group type: EXPERIMENTAL
Intervention: Subacromial injection of a mixture of 0.5 mL (2.5 mg) betamethasone acetate and 3 mL of radiographic contrast material (iotrolan) and 7 mL of 1% lidocaine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Intradeltoid injection
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Subacromial injection
Number of subjects: 53
Study: 10402406

Group type: EXPERIMENTAL
Intervention: Group 1 (follicles aspirated before leading follicle was 10 mm)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Group 2 (follicles aspirated when dominant follicle was >10 mm)
Number of subjects: 19
Study: 7745355

Group type: EXPERIMENTAL
Intervention: Ifenprodil tartrate (60 mg a.d.)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 2292326

Group type: EXPERIMENTAL
Intervention: sobrerol granules 900 mg/day for up to 10 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 31492117

Group type: EXPERIMENTAL
Intervention: UKOS study (randomised study comparing two modes of neonatal ventilation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Virus study (observational study examining the impact of viral lower respiratory tract infections)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UKOS study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Virus study
Number of subjects: 0
Study: 29317414

Group type: EXPERIMENTAL
Intervention: Virtual therapy (VT) for 8 weeks, performing 3-5 upper limb exercises individualized to impairment severity and preference
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Virtual therapy (VT) for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study: 27440543

Group type: EXPERIMENTAL
Intervention: 3.4 g PS esters-enriched soy milk powder (2.0 g/d free PS in 30 g soy milk powder)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo soy milk powder
Number of subjects: 170
Study: 24721483

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound
Number of subjects: 2759

Group type: EXPERIMENTAL
Intervention: Ultrasound performed by a radiologist
Number of subjects: 2759

Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 2759
Study: 22564085

Group type: EXPERIMENTAL
Intervention: Humor in advertisements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondistracting positive stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral stimuli
Number of subjects: 0
Study: 20409444

Group type: EXPERIMENTAL
Intervention: Antidepressant continuation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Antidepressant discontinuation
Number of subjects: 70
Study: 17032708

Group type: EXPERIMENTAL
Intervention: Living Well with a Disability program
Number of subjects: 246
Study: 15937373

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 69

Group type: COMPARATOR
Intervention: Ayurveda
Number of subjects: 69

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 69
Study: 12481893

Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccine
Number of subjects: 0
Study: 10717833

Group type: EXPERIMENTAL
Intervention: Regimen A: 100 mg/m2 i.a. cisplatin followed by 5 day continuous intravenous infusion of 5‐fluorouracil (1 g/m2 per day)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Regimen B: i.a. high pressure chemo‐perfusion with 150 mg/m2 cisplatin and simultaneous intravenous infusion of 9 g/m2 sodium thiosulfate
Number of subjects: 103
Study: 7738934

Group type: EXPERIMENTAL
Intervention: Hodge pessary with support
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Super tampon
Number of subjects: 18

Group type: COMPARATOR
Intervention: No mechanical device
Number of subjects: 18
Study: 1962942

Group type: EXPERIMENTAL
Intervention: Splenoportography and arteriography of the liver with maiodyl
Number of subjects: 0
Study: 7025875

Group type: EXPERIMENTAL
Intervention: Extradural morphine (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular morphine (10 mg)
Number of subjects: 0
Study: 31571339

Group type: EXPERIMENTAL
Intervention: Combined pulsed and thermal radiofrequency (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thermal radiofrequency alone (Group B)
Number of subjects: 40
Study: 31145045

Group type: EXPERIMENTAL
Intervention: HEI-2010 composite scores
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Total dairy
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Total vegetable
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Sodium
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Combined calories from solid fats, alcoholic beverages, and added sugars
Number of subjects: 133